PAI-1 Overexpression in Valvular Interstitial Cells Contributes to Hypofibrinolysis in Aortic Stenosis.
LDL
aortic stenosis
fibrinolysis
nuclear factor kappa B
plasminogen activator inhibitor 1
valve interstitial cells
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
16 05 2023
16 05 2023
Historique:
received:
23
03
2023
revised:
11
05
2023
accepted:
15
05
2023
medline:
7
7
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
Aortic stenosis (AS) is associated with hypofibrinolysis, but its mechanism is poorly understood. We investigated whether LDL cholesterol affects plasminogen activator inhibitor 1 (PAI-1) expression, which may contribute to hypofibrinolysis in AS. Stenotic valves were obtained from 75 severe AS patients during valve replacement to assess lipids accumulation, together with PAI-1 and nuclear factor-κB (NF-κB) expression. Five control valves from autopsy healthy individuals served as controls. The expression of PAI-1 in valve interstitial cells (VICs) after LDL stimulation was assessed at protein and mRNA levels. PAI-1 activity inhibitor (TM5275) and NF-κB inhibitor (BAY 11-7082) were used to suppress PAI-1 activity or NF-κB pathway. Clot lysis time (CLT) was performed to assess fibrinolytic capacity in VICs cultures. Solely AS valves showed PAI-1 expression, the amount of which was correlated with lipid accumulation and AS severity and co-expressed with NF-κB. In vitro VICs showed abundant PAI-1 expression. LDL stimulation increased PAI-1 levels in VICs supernatants and prolonged CLT. PAI-1 activity inhibition shortened CLT, while NF-κB inhibition decreased PAI-1 and SERPINE1 expression in VICs, its level in supernatants and shortened CLT. In severe AS, valvular PAI-1 overexpression driven by lipids accumulation contributes to hypofibrinolysis and AS severity.
Identifiants
pubmed: 37408236
pii: cells12101402
doi: 10.3390/cells12101402
pmc: PMC10216522
pii:
doi:
Substances chimiques
Lipids
0
NF-kappa B
0
Plasminogen Activator Inhibitor 1
0
SERPINE1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Thromb Haemost. 2011 Feb;105(2):254-60
pubmed: 21057695
J Thromb Haemost. 2013 Apr;11(4):733-40
pubmed: 23289423
Thromb Haemost. 2015 Aug;114(2):217-27
pubmed: 25809537
Cardiovasc Diabetol. 2020 Jun 17;19(1):92
pubmed: 32552684
Cardiovasc Pathol. 2005 Mar-Apr;14(2):80-7
pubmed: 15780799
Cardiovasc Ther. 2010 Oct;28(5):e72-91
pubmed: 20626406
Atherosclerosis. 2014 Mar;233(1):104-12
pubmed: 24529130
J Clin Med. 2020 Jun 25;9(6):
pubmed: 32630544
Am J Pathol. 2007 Nov;171(5):1407-18
pubmed: 17823281
PLoS One. 2016 Feb 11;11(2):e0148747
pubmed: 26866684
Diabetologia. 2021 Nov;64(11):2562-2574
pubmed: 34494136
J Cell Biochem. 2015 Nov;116(11):2427-34
pubmed: 25974396
Clin Cancer Res. 1999 Aug;5(8):2094-102
pubmed: 10473092
Arterioscler Thromb Vasc Biol. 2020 Jun;40(6):1479-1490
pubmed: 32268785
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4704-12
pubmed: 27607416
J Pathol. 2010 May;221(1):37-48
pubmed: 20186923
J Am Coll Cardiol. 2015 Aug 4;66(5):561-77
pubmed: 26227196
Atherosclerosis. 2022 Mar;344:49-56
pubmed: 35134656
Am J Physiol Cell Physiol. 2008 Jan;294(1):C29-35
pubmed: 17942642
Thromb Res. 2013 Jul;132(1):100-5
pubmed: 23611258
Int J Mol Sci. 2020 Jul 21;21(14):
pubmed: 32708302
EuroIntervention. 2022 Feb 04;17(14):e1126-e1196
pubmed: 34931612
J Thromb Haemost. 2003 Nov;1(11):2389-96
pubmed: 14629474
Int J Mol Sci. 2020 Sep 25;21(19):
pubmed: 32993026
Thromb J. 2018 Jun 05;16:12
pubmed: 29991926
J Thromb Haemost. 2018 May;16(5):1007-1012
pubmed: 29658191
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1370-1382
pubmed: 32188274
Vascul Pharmacol. 2020 Jul;130:106679
pubmed: 32387621
J Am Coll Cardiol. 1993 Apr;21(5):1220-5
pubmed: 8459080